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Safety and Efficacy of Antiplatelet and Antithrombotic
Therapy in Acute Coronary Syndrome
Patients With Chronic Kidney Disease
Sukhdeep S. Basra, MD, MPH,* Peter Tsai, MD,† Nasser M. Lakkis, MD*‡
Houston, Texas
Chronic kidney disease (CKD) is prevalent and affects an ever-increasing proportion of patients presenting with
acute coronary syndrome (ACS). Patients with CKD have a higher risk of ACS and significantly higher mortality,
and are also predisposed to increased bleeding complications. Antiplatelet and antithrombotic drugs form the
bedrock of management of patients with ACS. Most randomized trials of these drugs exclude patients with CKD,
and current guidelines for management of these patients are largely based on these trials. We aim to review the
safety and efficacy of these drugs in patients with CKD presenting with ACS. (J Am Coll Cardiol 2011;58:2263–9)
© 2011 by the American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.08.051b
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PChronic kidney disease (CKD) as defined by the National
Kidney Foundation includes a mild reduction of glomerular
filtration rate (GFR) in the presence of kidney damage
(stage 2), and moderate to severe reductions in GFR even in
the absence of kidney damage (stages 3 to 5) (Table 1). The
National Kidney Foundation estimates that 11% of the U.S.
population has CKD (1). Data from clinical trials suggest
that 35% to 40% of patients presenting with an acute
coronary syndrome (ACS) have some degree of renal
insufficiency (2,3). Chronic kidney disease is an independent
predictor of outcome in patients presenting with ACS.
Cardiovascular disease is the leading cause of death in
patients with CKD (1,4).
Patients with renal insufficiency are known to have a
graded increased risk for thrombosis (5) and bleeding (6,7).
Uremia is associated with prolongation of bleeding time and
abnormal platelet aggregation and adhesion due to intrinsic
and extrinsic factors (Fig. 1) (8). The American College of
Cardiology (ACC) and American Heart Association
(AHA) guidelines for management of ACS clearly ac-
knowledge the lack of sufficient studies so as to make
specific recommendations for patients with CKD (9). A
ecent study showed that patients with CKD were excluded
rom 75% of published coronary artery disease trials (10). It
s extremely important for practitioners to become familiar
ith the sites of action of all the antiplatelet and antithrom-
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2011, accepted August 21, 2011.otic drugs, as shown in Figure 2, to make judicial decisions
egarding CKD patients. Table 2 also shows the recom-
ended dose, half-life, route of elimination, and dose
djustment of most approved anticoagulants, as well as
otential methods to reverse bleeding for each of these
gents.
ntiplatelet and Antithrombotic Drugs
he antiplatelet and antithrombotic drugs used for treating
atients with CKD are shown in Table 3.
spirin. The efficacy of aspirin for patients with CKD
resenting with ACS is well established. In the Cooperative
ardiovascular Project (11), McCullough et al. (12) showed
hat aspirin reduced in-hospital mortality by 64.3% to 80%
cross all quartiles of creatinine clearance (CrCl). In addi-
ion, patients who were not receiving aspirin on admission
ere more likely to be in heart failure or cardiogenic shock.
recent retrospective review of 595 patients with ACS
ound that the use of aspirin was associated with a decreased
ate of ST-segment elevation myocardial infarction in pa-
ients with GFR 60 ml/min (odds ratio [OR]: 0.5, 95%
onfidence interval [CI]: 0.2 to 1.0; p  0.05) (13). Data
rom the National Cardiovascular Data ACTION (Acute
oronary Treatment and Intervention Outcomes Network)
egistry, including 19,029 patients with ST-segment eleva-
ion myocardial infarction and 30,462 with non–ST-
egment elevation myocardial infarction, documented de-
reasing use of aspirin with worsening severity of CKD
14,15). The U.K. HARP (Heart and Renal Protection)-1
rial and the DOPPS (Dialysis Outcomes and Prescription
atterns Study) showed that low-dose aspirin (100 mg/day)n CKD patients was not associated with increased major
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(16,17). In a recent meta-analysis
by the Antithrombotic Trialists
Collaboration, low-dose aspirin
(75 to 160 mg) was found to be
as efficacious as high-dose aspirin
(325 mg) beyond the acute phase
for secondary prevention of cor-
onary artery disease in patients
with CKD and end-stage renal
disease (18).
Clopidogrel. The current ACC/
AHA guidelines recommend the
use of clopidogrel in patients with
ACS (9,19). No specific recom-
mendations exist for the adjust-
ment of clopidogrel dosage in renal
insufficiency. A post-hoc analysis
from the CREDO (Clopidogrel
for Reduction in Events During
Observation) trial, patients with
mild and moderate CKD did not have any significant
difference in outcomes (mild 10.3 % vs. 12.8%, p  0.30;
oderate 17.8% vs. 13.1%, p  0.24) with increased risk of
leeding with clopidogrel (20).
A post-hoc analysis of the CURE (Clopidogrel in Unstable
ngina to Prevent Recurrent Events) trial (21–23) showed no
nteraction between clopidogrel and renal function (p value for
omogeneity 0.11). However, there was no significant benefit
rom using clopidogrel for patients in the lowest tertile (relative
isk: 0.89 [95% confidence interval [CI]: 0.76 to 1.05]), and
atients in this group had a significant increase in minor
leeding (hazard ratio: 1.5, 95% CI: 1.21 to 1.86) and blood
ransfusion (3.5%).
Deray et al. (24), compared platelet inhibition using 75
g of clopidogrel in patients with moderate and severe
KD, and demonstrated similar clopidogrel-induced plate-
et inhibition in both groups. Park et al. (25) compared
lopidogrel responsiveness in normal persons (n  23) and
atients with CKD treated with 75 mg (n  18) and 150
g (n  18) of clopidogrel. They found decreased platelet
inhibition in patients with CKD even with doubling the
dose of clopidogrel (25). A recent study by Cuisset et al. (26)
evaluated the effect of CKD on platelet aggregation in
patients with ACS given clopidogrel (600 mg loading dose
followed by 150 mg daily). There was no difference in
platelet aggregation acutely and at 30 days. Clinical effect of
CKD in patients administered double-dose clopidogrel in
the OASIS-7 (Seventh Organization to Assess Strategies in
Acute Coronary Syndrome) trial is not available.
Prasugrel. Prasugrel is a third-generation thienopyridine
(27–29). Small et al. (30) conducted a study comparing the
pharmacokinetics and pharmacodynamics of prasugrel in
patients with normal renal function, moderate renal insuf-
ficiency, and end-stage renal disease. The levels of the active
Abbreviations
and Acronyms
ACC  American College of
Cardiology
ACS  acute coronary
syndrome(s)
AHA  American Heart
Association
AMI  acute myocardial
infarction
CI  confidence interval
CKD  chronic kidney
disease
CrCl  creatinine clearance
GFR  glomerular filtration
rate
GPI  glycoprotein IIb/IIIa
inhibitor
OR  odds ratiometabolite of prasugrel were not affected by moderate renalimpairment, but decreased by 40% in end-stage renal
disease, although with similar platelet inhibition levels.
Inhibition of platelet aggregation was similar in all groups
(30). So far, there are no studies on clinical outcomes with
prasugrel in patients with CKD.
Ticagrelor. Ticagrelor is a more potent inhibitor of platelet
aggregation (31,32). A subanalysis of the PLATO (Ticagrelor
versus Clopidogrel in Patients in Acute Coronary Syndrome)
trial showed CKD patients (GFR 60 ml; n  3,237) have a
reater reduction in events (17.3% vs. 22%; hazard ratio: 0.77
95% CI: 0.65 to 0.90]) and mortality (10% vs. 14%; hazard
atio: 0.72 [95% CI: 0.58 to 0.89]) as compared to non-CKD:
.7% per year vs. 1% per year, respectively (34). Ticagrelor offers an
lternative option for treating ACS patients with CKD.
lycoprotein IIb/IIIa inhibitors. Intravenous glyco-
rotein IIb/IIIa inhibitors (GPIs) block the final pathway
or platelet aggregation (34,35). Frilling et al. (36) compared
he efficacy of abciximab in normal and CKD patients.
atients in either group had similar clinical outcomes. The
KD patients had more episodes of major bleeding (4.5%
s. 0.6%; p  0.003) but similar episodes of minor bleeding
nd thrombocytopenia. Similar findings were reported by
he Mayo Clinic (37). A recent study by Pinkau et al. (38)
valuated adding abciximab to aspirin and clopidogrel in
KD patients undergoing PCI. There was no significant
nteraction between abciximab, renal function, and bleeding
omplications (p  0.22). Alam et al. (38) showed that
atients with CrCl 60 ml/min have 10% platelet aggre-
ation at 25 ng/ml tirofiban, one-third the standard effective
ose in non-CKD patients.
A subgroup analysis of the PRISM-PLUS (Platelet Recep-
or Inhibition in Ischemic Syndrome Management in Patients
imited by Unstable Signs and Symptoms) trial showed that
IMI (Thrombolysis In Myocardial Infarction) major bleed-
ng was not significantly worsened by renal dysfunction or the
se of tirofiban (p  0.35 and p  0.20, respectively).
owever, the combined endpoint of TIMI major and minor
leeding was increased with worsening renal function (p 
.004) as well as use of tirofiban (p  0.04).
A subanalysis of the TARGET (Do Tirofiban and
eoPro Give Similar Efficacy Outcome) trial (40) based on
reatinine clearance (70, 70 to 90, 90 to 114, and 114
l/min) showed that patients with lower CrCl have higher
schemic and bleeding events. The ESPRIT (Enhanced
National Kidney FoundationClassificat o of CKD Based on GFRTable 1 National Kidn y FoundationClassification of CKD Based on GFR
Classification Definition
Normal GFR 90 ml/min/1.73 m2 with no evidence of kidney dysfunction
CKD 1 GFR 90 ml/min/1.73 m2 with evidence of kidney dysfunction
CKD 2 GFR 60–90 ml/min/1.73 m2
CKD 3 GFR 30–60 ml/min/1.73 m2
CKD 4 GFR 15–30 ml/min/1.73 m2
CKD 5 GFR 15 ml/min/1.73 m2CKD  chronic kidney disease; GFR  glomerular filtration rate.
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rilin Therapy) trial (41–43) showed that treatment benefit
with eptifibatide was seen irrespective of renal function, and
Figure 1 Overview of Factors Contributing to Platelet Dysfunct
Shown are both intrinsic and extrinsic coagulation factors contributing to platelet d
activation, and aggregation in uremic patients. ADP  adenosine diphosphate. Ad
Figure 2 Sites of Inhibition of Platelet Activation and Aggregat
The sites of inhibition of platelet activation and aggregation by all currently approv
ADP  adenosine diphosphate; GP  glycoprotein; TxA  thromboxane A ; wWF2 2it was greater in patients with mild renal insufficiency. Data
from the PROTECT trial (44) and the CRUSADE (Can
Rapid Risk Stratification of Unstable Angina Patients
Uremia
tion in uremia, demonstrating the mechanism of impaired platelet adhesion,
with permission from Washam and Adams (8).
icoagulants are detailed.
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the American College of Cardiology/American Heart As-
sociation Guidelines) National Quality Improvement Reg-
istry found that bleeding risk is higher in patients admin-
istered excess doses of GPIs (OR: 1.36; 95% CI: 1.10 to
1.68), and it is further increased in patients with renal
insufficiency (OR 4.12; 95% CI: 2.65 to 5.75). These data
further underscore the importance of calculating the CrCl
before administering GPIs (45).
Heparin. Unfractionated heparin reduces early ischemic
events in patients with ACS with and without CKD
(45– 48). The half-life of enoxaparin in dialysis patients is
twice as long as in healthy volunteers. The total clearance
of enoxaparin is 1.9 times lower and its half-life 1.7 times
longer in patients with renal insufficiency (49 –57). A
retrospective study evaluated the outcomes of bleeding
and death in patients with CKD administered enoxaparin
demonstrated an increase in total bleeding, major bleeding
as well as deaths (58). A recent substudy of the EXTRACT
(Enoxaparin and Thrombolysis Reperfusion for Acute Myo-
cardial Infarction Treatment)–TIMI 25 trial showed that with
every 30 ml/min decrease in CrCl, the risk of major and minor
bleeding increased by 50% (59).
Fondaparinux. Fondaparinux is a synthetic heparin ana-
logue that causes an irreversible conformational change in
Antiplatelet and Antithrombotic Agents, Recommended Doses, RouEffect of Renal Failure on D se, and Potential Strategies to ReversTable 2 A tipla elet and Antithrombotic Agents, R comm ndeEffect of Renal Failure on Dose, and Potential Strategi
Drug Recommended Dose
Route of
Elimination Ha
Aspirin 81–325 mg Renal (pH-
dependent)
2–19 h
Clopidogrel
and active
metabolite
Loading dose: 300–600 mg
Maintenance dose: 75 mg
Renal (50%),
feces (50%)
6 h
Prasugrel Loading dose: 60 mg
Maintenance dose: 10 mg
Renal (60–70%) 2–15 h
Ticagrelor Loading dose: 180 mg
Maintenance dose: 90 mg PO BID
Biliary 6–13 h
Abciximab 250 g/kg bolus followed by
0.125 g/kg/min for 12 h
Spleen, RES 30 min
Tirofiban 0.4 g/kg/min 30-min bolus
followed by 0.1 g/kg/min
Renal (40%–70%) 1.4–1.8 h
Epitifibatide 180 g/kg bolus followed by
2.0 g/kg/min for 72 h
Renal (50%) 25 min
Unfractionated
heparin
PTT: 50–70 s RES 1–1.5 h
Enoxaparin 1 mg/kg SC every 12 h Renal (40%) 4–7 h
Fondaparinux 2.5 mg SC daily Renal 17–21 h Incr
failure
Bivalirudin 0.75 mg/kg IV bolus followed by
1.75 mg/kg/h during
procedure
Renal 25 min Incre
CrCl30m
BID  twice a day; CrCl  creatinine clearance; FFP  fresh frozen plasma; IV  intravenous; POantithrombin. Fondaparinux is given a class I ACC/AHA Crecommendation in ACS patients with high bleeding risk.
In the OASIS-5 (Fifth Organization to Assess Strategies in
Acute Coronary Syndrome) trial (59), the composite end-
point was lower with fondaparinux compared to enoxaparin
and reached significance only in patients with GFR 58
l/min/1.73 m2. The rates of bleeding were lower across all
uartiles of renal dysfunction.
ivalirudin. Bivalirudin is a synthetic direct thrombin
nhibitor with a half-life of 25 min and significant renal
learance (62–64). In a substudy of the ACUITY (Acute
atheterization and Urgent Intervention Triage Strategy)
rial (62) in CKD patients, there were fewer bleeding
omplications with bivalirudin than with unfractionated
eparin plus GPI (65). However, as bivalirudin is renally
leared, patients with CrCl 30 ml/min should not receive
ivalirudin as most of these patients were excluded from the
CUITY trial.
irect factor Xa inhibitors. Currently, a number of
irect factor Xa inhibitors are being evaluated in clinical
rials in patients with ACS (66,67). Dabigatran (68 –71)
s a recently approved Xa inhibitor in patients with
onvalvular atrial fibrillation. The half-life of dabigatran
ncreases with renal dysfunction, and its use is contrain-
icated in patients with CrCl 30 ml/min/1.73 m2 (69).
ata on the safety and efficacy of these agents for treating
f Elimination,ir Effectes, Rou es of Elimination,
Reverse Their Effect
Effect of Renal Failure on Dose
Strategy for Reversal in Patients
With Bleeding
None Discontinue; platelet transfusion,
and desmopressin
None Discontinue; platelet transfusions
and desmopressin
None Discontinue; platelet transfusions
and desmopressin
None Discontinue
None Discontinue; platelet transfusions
and desmopressin
CrCl 30 ml/min/1.73 m2:
0.2 g/kg/min 30-min bolus
followed by 0.05 g/kg/min
Discontinue; FFP
CrCl 50 ml/min/1.73 m2:
180 g/kg/min bolus followed
by 1 g/kg/min for 72 h;
contraindicated in patients on
hemodialysis
Discontinue; FFP
None Protamine
Decrease to 1 mg/kg SC daily Partial reversibility (2/3) to
protamine
in renal Avoid if CrCl 30 ml/min/1.73 m2 Recombinant factor VIIa (90 g/kg)
Based on laboratory data only
/1.73m2
Avoid if CrCl 30 ml/min/1.73 m2 No single antidote; may consider
hemodialysis
ly; PTT  partial thromboplastin time; RES  reticuloendothelial system; SC  subcutaneously.tes oe Thed Dos
es to
lf-Life
eases
ases if
l/minKD are lacking.
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There is a clear dearth of studies evaluating the safety and
efficacy of these drugs for treating CKD patients, and
most of the recommendations are based on single-center
data or post-hoc analyses. Novel therapies may help
overcome some of the complications observed in these
patients, but further randomized trials are warranted to
objectively evaluate their efficacy for this increasingly
Safety and Efficacy of Antiplatelet and Antithrombotic Agents StraTable 3 Safety and Efficacy of Antiplatelet and Antithrombotic
Drug CKD 1 CKD 2 CKD 3 CKD 4 CKD 5
Aspirin S, E S, E S, E S, E S, E
Clopidogrel S, E S, E US, NE US, NE US, NE Increase
of bloo
Lack o
CURE
studie
standa
clopid
Prasugrel S, E S, E UK UK UK No studi
and ef
differe
and ph
Ticagrelor S, E S, E S, E S, E S, E May be c
clopid
assess
clopid
Abciximab S, E S, E S, E S, E S, E No intera
abcixim
and is
Tirofiban S, E S, E S, E S, E S, E No intera
tirofib
and is
Dose n
30 m
Eptifibatide S, E S, E S, E S, E S, E No intera
eptifib
and is
Dose n
50 m
Unfractionated
heparin
S, E S, E S, E S, E S, E May be p
LMWH S, E S, E S, E US, E US, E Increase
bleedi
reduce
30 m
prefer
Fondaparinux S, E S, E S, E A A May be p
with G
58 ml
CrCl 
Bivalirudin S, E S, E S, E A A Superior
underg
fewer
compl
30 m
Direct factor Xa
inhibitors
UK UK UK UK UK No studi
these
curren
A  avoid; E  effective; GPI  glycoprotein inhibitor; LMWH  low molecular weight heparin
RCT  randomized clinical trial; RP  retrospective; S  safe; SA  subanalysis; SC  single c
1 and 2.common subgroup of patients.Reprint requests and correspondence: Dr. Nasser M. Lakkis,
Section of Cardiology, Baylor College of Medicine, 1504 Taub
Loop, Houston, Texas 77030. E-mail: nlakkis@bcm.edu.
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